Syrmou Vasiliki, Liaskos Christos, Patrikious Eleni, Alexiou Ioannis, Simopoulou Theodora, Katsiari Christina G, Bogdanos Dimitrios P
Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, University General Hospital of Larissa, Larissa, Greece.
Mediterr J Rheumatol. 2025 Jun 30;36(2):200-209. doi: 10.31138/mjr.300525.iao. eCollection 2025 Jun.
Anti-transcription intermediary factor 1-gamma (anti-TIF1γ) antibodies are closely associated with Inflammatory myositis (IIM) and cancer-associated myositis.
Description of clinical characteristics of anti-TIF1γ(+) IIM patients in a Greek population.
MATERIAL & METHODS: Retrospective analysis with 113 IIM cases between 2001 and 2024 was performed and clinical and laboratory data were collected. Disease manifestations and outcomes were compared between anti-TIF1γ-positive and -negative groups.
Twenty patients (17.7%) were anti-TIF1γ(+), of which 70% were women. The mean age was 64.8 ± 12.5 years vs 59.61 ± 12.81 of anti-TIF1γ(-) patients (p>0.05). Anti-TIF1γ was strongly associated with Dermatomyositis (DM) (95%, p < 0.001) and more severe cutaneous involvement (mean CDASI=27.35 ± 15.01 vs 14 ± 12.25 p =0.0015). Malignancy was significantly more frequent in the anti-TIF1γ(+) group (60% vs. 20.4%, p = 0.001), with an odds ratio of 5.84 (95% CI 2.09-16.31). Logistic regression identified anti-TIF1γ positivity as independent predictor of malignancy. Interstitial Lung Disease was uncommon among anti-TIF1γ(+) cases (15%, p = 0.004), while dysphagia was far more prevalent (55% vs. 22.6%, p = 0.001). Muscle power (MMT-8score) and CPK levels did not differ significantly, and survival was lower in anti-TIF1γ(+) patients (55.7% vs. 82.6% p<0.001), associated with malignancy.
In our cohort, anti-TIF1γ antibodies define a distinct IIM subset marked by severe skin disease, high malignancy risk, and poorer survival, supporting comprehensive cancer screening and tailored immunosuppressive treatment. This study describes this phenotype in a Greek cohort, aligning with international evidence and highlighting the need for collaborative studies.
抗转录中介因子1-γ（抗TIF1γ）抗体与炎性肌病（IIM）及癌症相关性肌炎密切相关。
描述希腊人群中抗TIF1γ（+）IIM患者的临床特征。
对2001年至2024年间的113例IIM病例进行回顾性分析，并收集临床和实验室数据。比较抗TIF1γ阳性和阴性组的疾病表现及预后。
20例患者（17.7%）抗TIF1γ（+），其中70%为女性。平均年龄为64.8±12.5岁，而抗TIF1γ（-）患者为59.61±12.81岁（p>0.05）。抗TIF1γ与皮肌炎（DM）密切相关（95%，p<0.001），且皮肤受累更严重（平均CDASI=27.35±15.01 vs 14±12.25，p=0.0015）。抗TIF1γ（+）组恶性肿瘤的发生率显著更高（60% vs. 20.4%，p=0.001），优势比为5.84（95%CI 2.09-16.31）。逻辑回归分析确定抗TIF1γ阳性是恶性肿瘤的独立预测因素。抗TIF1γ（+）病例中间质性肺病不常见（15%，p=0.004），而吞咽困难更为普遍（55% vs. 22.6%，p=0.001）。肌肉力量（MMT-8评分）和肌酸磷酸激酶水平无显著差异，抗TIF1γ（+）患者的生存率较低（55.7% vs.
